These gains partially offset headwinds, including the continued impact of the loss of exclusivity (LOE) for Atozet and challenges that emerged during the year. Morrissey highlighted policy-related changes in the U.S. affecting Nexplanon access and a revision to medical guidelines in certain international markets that deprioritized montelukast, impacting SINGULAIR.Biosimilars , driven primarily by HADLIMA and additional contributions from a denosumab biosimilar launch and TOFIDENCE, which Organon acquired in ...

Organon (NYSE:OGN) Q4 2025 Earnings call February 12, 2026 08:30 AM ET Company ParticipantsCarrie Cox - Board ChairJennifer Halchak - VP of Investor RelationsJoe Morrissey - Interim CEOJuan Camilo Arjona Ferreira - Head of R&DMatt Walsh - CFOMike Nedelcovych - Director of Equity ResearchPavan Patel - Associate, Biotechnology and Pharmaceuticals Equity ResearchUmer Raffat - Senior Managing DirectorConference Call ParticipantsEthan Brown - Equity Research AnalystTerence Flynn - Equity Research AnalystNone - A ...